1 day Ago By ABMN Staff
Aldeyra Therapeutics ( NASDAQ:ALDX – Get Free Report ) is projected to announce its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.25) per share and revenue of ($0.
80) million for the quarter. Aldeyra Therapeutics ( NASDAQ:ALDX – Get Free Report ) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($0.
27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30).
On average, analysts expect Aldeyra Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year. Aldeyra Therapeutics Trading Down 2.5 % Shares of Aldeyra Therapeutics stock opened at $2.
69 on Wednesday. Aldeyra Therapeutics has a 52-week low of $1.14 and a 52-week high of $7.
20. The company has a quick ratio of 6.80, a current ratio of 6.
80 and a debt-to-equity ratio of 0.18. The company’s 50-day simple moving average is $4.
60 and its 200-day simple moving average is $5.02. The firm has a market cap of $160.
62 million, a price-to-earnings ratio of -2.86 and a beta of 0.94.
Insider Buying and Selling at Aldeyra Therapeutics Analyst Ratings Changes ALDX has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Friday, April 4th.
BTIG Research decreased their price objective on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, April 7th.
Read Our Latest Report on ALDX About Aldeyra Therapeutics ( Get Free Report ) Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Read More Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
